|Values are valid only on day of printing.|
Inflammatory bowel disease (IBD) refers to 2 diseases, ulcerative colitis (UC) and Crohn's disease (CD), that produce inflammation of the large or small intestines.(1) The diagnoses of both diseases are based on clinical features, the results of barium X-rays, colonoscopy, mucosal biopsy histology, and in some cases operative findings and resected bowel pathology and histology.
Recently, patients with IBD have been shown to have antibodies in serum that help distinguish between CD and UC.(2) Patients with UC often have measurable neutrophil-specific antibodies, which react with as yet uncharacterized target antigens in human neutrophils; whereas, patients with CD often have measurable antibodies of the IgA and/or IgG isotypes, which react with cell wall mannan of Saccharomyces cerevisiae strain Su 1.
Helping clinicians distinguish between ulcerative colitis and Crohnâ€™s disease in patients suspected of having inflammatory bowel disease
In IBDP / Inflammatory Bowel Disease Serology Panel, Serum, anti-Saccharomyces cerevisiae antibodies (ASCA) and neutrophil-specific antibodies (NSA) are measured. The finding of NSA with normal levels of IgA and IgG ASCA is consistent with the diagnosis of ulcerative colitis (UC); the finding of negative NSA with elevated IgA and IgG ASCA is consistent with Crohn's disease (CD).
NSA are detectable in approximately 50% of patients with UC.
Elevated levels of either IgA or IgG ASCA occur in approximately 55% of patients with CD.
Approximately 40% of patients with CD have elevated levels of both IgA and IgG ASCA.
Employed together, the tests for NSA and ASCA have the following positive predictive values (PPV) for UC and CD, respectively:(2)
-NSA-positive with normal levels of IgA and IgG ASCA, PPV of 91%
-NSA-negative with elevated levels of IgA and IgG ASCA, PPV of 90%
IBDP / Inflammatory Bowel Disease Serology Panel, Serum is useful as an adjunct in the diagnosis of ulcerative colitis (UC) and Crohnâ€™s disease (CD), but should not be relied upon exclusively to establish the diagnosis of UC or CD, or to distinguish between these 2 diseases. Some patients with CD have detectable neutrophile-specific antibodies (NSA), and some patients with UC have elevated levels of IgA and/or IgG anti-Saccharomyces cerevisiae antibodies (ASCA).
Measurement of ASCA and NSA are not useful to determine the extent of disease in patients with inflammatory bowel disease or to determine the response to disease-specific therapy including surgical resection of diseased intestine.
Negative: < or =20.0 U
Equivocal: 20.1-24.9 U
Weakly positive: 25.0-34.9 U
Positive: > or =35.0 U
Reference values apply to all ages.
1. The Autoimmune Diseases: Inflammatory Bowel Diseases. Edited by NR Rose, IR Mackay. New York, NY, Elsevier Academic Press, 2008
2. Sandborn WJ, Loftus EV Jr, Homburger HA, et al: Evaluation of serological disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2001 Aug;7(3):192-201